^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LMNA-NTRK1 fusion

    i
    Other names: LMNA, Prelamin-A/C, LMN1, Mandibuloacral dysplasia type A, Limb girdle muscular dystrophy 1B (autosomal dominant), Cardiomyopathy dilated 1A (autosomal dominant), Lamin A/C, FPLD2, LGMD1B, CMT2B1, Renal carcinoma antigen NY-REN-32, Progeria 1 (hutchinson-gilford type), NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
    Entrez ID:
    4914; 4000
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    1year
    LMNA::NTRK1 and PRDX1::NTRK1 Atypical Spitz Tumor: A Report of Two Additional Cases With Histological, Immunohistochemical, and Molecular Insights. (PubMed, Am J Dermatopathol)
    Clinical, histopathological, immunohistochemical, and molecular analyses were performed to diagnose these patients. This report adds to the growing body of knowledge on NTRK-rearranged Spitz lesions and underscores the importance of integrating molecular findings with morphological and immunohistochemical data for the accurate classification and understanding of these neoplasms.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • PRDX1 (Peroxiredoxin 1) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK2 fusion • LMNA-NTRK1 fusion
    1year
    NTRK-rearranged spindle cell neoplasms – report of two cases with divergent morphology (ECP 2024)
    Identifying patients with NTRK gene fusions is crucial, as they could benefit from targeted therapy using TRK inhibitors. This requires a detailed description of emerging entities like NTRK-RSCNs because testing for NTRK rearrangement is not routinely performed. In two cases, we report a spectrum of histological grades, including a high-grade phenotype.
    Clinical
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CD34 (CD34 molecule) • LMNA (Lamin A/C) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • NTRK (Neurotrophic receptor tyrosine kinase) • STAT6 (Signal transducer and activator of transcription 6) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    NTRK1 fusion • LMNA-NTRK1 fusion • NTRK fusion
    |
    Archer® FusionPlex® Sarcoma kit
    over1year
    Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort. (PubMed, Hum Pathol)
    FISH could complement NGS detection, particularly when NTRK fusion is detected by DNA sequencing. NTRK fusion in GC may not be limited to specific subtypes.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • LMNA-NTRK1 fusion • NTRK1 mutation • NTRK fusion
    almost2years
    Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling. (PubMed, Cancers (Basel))
    The correlations between the MAPK pathway G1-G7 subgroups and the PI3-kinase/PTEN, TERT, cell cycle G1 phase and p53 pathways defined characteristic subgroup pathway profiles amenable to personalized targeted therapy. This analysis validated the first all-inclusive molecular classification of glioblastoma, showed significant demographic and molecular differences between subgroups, and provided the first ethnic molecular comparison of glioblastoma.
    Journal • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NF1 (Neurofibromin 1) • LMNA (Lamin A/C) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    EGFR mutation • NTRK1 fusion • NF1 mutation • ROS1 fusion • GOPC-ROS1 fusion • LMNA-NTRK1 fusion • NTRK1 overexpression
    2years
    Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. (PubMed, Clin Orthop Relat Res)
    DNA- and RNA-based screening systems may be useful for detecting tyrosine kinase fusion genes in specific fusion-negative sarcomas and identifying key therapeutic targets, leading to possible breakthroughs in the treatment of bone and soft tissue sarcomas. Given that current DNA sequencing misses fusion genes, RNA-based screening systems should be widely considered as a worldwide test for sarcoma. If standard treatments such as chemotherapy are not effective, or even if the sarcoma is of bone, RNA sequencing should be considered to identify as many therapeutic targets as possible.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • KDR (Kinase insert domain receptor) • CDK4 (Cyclin-dependent kinase 4) • LMNA (Lamin A/C) • CLTC (Clathrin Heavy Chain) • NTRK (Neurotrophic receptor tyrosine kinase) • CEP290 (Centrosomal Protein 290) • FOXP2 (Forkhead Box P2)
    |
    NTRK1 fusion • NTRK3 fusion • ALK fusion • LMNA-NTRK1 fusion • NTRK3 positive • NTRK positive • NTRK fusion
    |
    TruSight Tumor 170 Assay
    |
    Vitrakvi (larotrectinib)
    2years
    The association between neurotrophic tropomycin receptor kinase (NTRK) variants of unknown significance (VUS’s) and response to immune checkpoint inhibitors in solid tumors (SITC 2023)
    The statistical significance was limited to NTRK3 alterations but a trend for better mOS was evident in NTRK1 and NTRK2. Propsective validation and efforts to understand the underlying mechansims are warranted.
    Checkpoint inhibition • IO biomarker
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • LMNA-NTRK1 fusion • NTRK fusion
    2years
    Expanding the Spectrum of Fusion-driven Melanocytic Lesions: A Series of 4 Cases (ASDP 2023)
    The spectrum of fusion-driven melanocytic lesions is rapidly expanding with the democratization of molecular testing. Tumors with CRTC1 :: TRIM11 are now known for their metastatic potential. Precise characterization of these entities may inform patient follow-up and management, including the opportunity for kinase inhibitor therapies.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • LMNA (Lamin A/C) • WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2) • CRTC1 (CREB Regulated Transcription Coactivator 1)
    |
    TMB-H • NTRK1 fusion • LMNA-NTRK1 fusion
    over2years
    A child with LMNA-NTRK1 rearranged spindle cell neoplasm (EADV 2023)
    All the findings confirmed the diagnosis of LMNA-NTRK1 rearranged spindle cell neoplasm, a recently described and rare molecularly-defined soft tissue tumor that may have a wide spectrum of morphologies and histological grades, with frequent co-expression of CD34 and S100. Due to the highly infiltrative growth pattern, the tumor has a propensity for local recurrence, if incompletely excised, but none has been shown to metastasize. In our patient, there was no recurrence more than 3 years after the excision.
    Clinical
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CD34 (CD34 molecule) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • LMNA-NTRK1 fusion
    over2years
    Evaluating Gene Fusions in Solid Tumors by Next- Generation Sequencing: A Tertiary Centre Experience (AMP Europe 2023)
    "Gene fusions represent crucial targets in the context of precision medicine. NGS testing for fusion detection not only allows analysis of multiple targets but also saves time and material. The identification of novel fusions in this study also highlights the potential for future therapeutic targets."
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ETV6 (ETS Variant Transcription Factor 6) • LMNA (Lamin A/C) • DCTN1 (Dynactin Subunit 1) • AGK (Acylglycerol Kinase) • SDC4 (Syndecan 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • NTRK1 fusion • MET exon 14 mutation • ROS1 positive • EGFRvIII mutation • FGFR1 fusion • FGFR3 fusion • LMNA-NTRK1 fusion • SDC4-ROS1 fusion • NTRK fusion
    |
    SOPHiA DDM™ Solid Tumor Plus Solution
    over2years
    Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant. (PubMed, Dig Liver Dis)
    Regarding break-apart FISH, NTRK detection is difficult because of the diversity of signal patterns. Further research is warranted to identify the characteristics of NTRK-fusion CRCs.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK1 fusion • NTRK3 fusion • ETV6-NTRK3 fusion • TPM3-NTRK1 fusion • LMNA-NTRK1 fusion • NTRK1 positive • NTRK positive • NTRK fusion
    3years
    Intestinal LMNA::NTRK1-fused spindle cell neoplasm with S100 and CD34 coexpression: a new case. (PubMed, BMJ Case Rep)
    Here, we present a recently encountered intestinal spindle cell neoplasm harbouring an LMNA::NTRK1 gene fusion in a woman in her early 20s, which was initially thought to represent a GIST or a solitary fibrous tumour. Awareness of this emerging tumour type in the gastrointestinal tract is important due to treatment implications.
    Journal
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • RAS (Rat Sarcoma Virus) • CD34 (CD34 molecule) • LMNA (Lamin A/C) • SOX10 (SRY-Box 10) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • BRAF wild-type • RAS wild-type • LMNA-NTRK1 fusion • PDGFR wild-type
    3years
    Pan-Solid Tumor Identification of NTRK Fusions Utilizing RNA Sequencing Identifies Diverse Fusion Partners (AMP 2022)
    NTRK1, NTRK2, and NTRK3 fusions are clinically relevant driver alterations across solid tumor types. These fusions are difficult to detect, as the breakpoints occur across large intronic regions and they have many partner genes, with 10 novel fusion partners identified in this study. These data emphasize how important CGP with RNA sequencing is to identify all NTRK fusions for optimal patient treatment.
    Tumor Mutational Burden • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • LMNA (Lamin A/C) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase) • PIAS4 (Protein Inhibitor Of Activated STAT 4) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha)
    |
    TMB-H • MSI-H/dMMR • KRAS G12C • HER-2 amplification • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK fusion • KRAS G13D • KRAS G12 • KRAS G13 • LMNA-NTRK1 fusion • NTRK fusion